[1] Ch.P(2020) Vol Ⅳ(中国药典2020年版.四部)[S]. 2020:133-134.
[2] ZHAO J, YI H, LIU X Q, et al. Progress in application of flow-through cell method for determination of drug dissolution[J]. Chin Pharm J(中国药学杂志), 2014, 49(17):1486-1490.
[3] YE X J, CHEN Y, et al. Dissolution testing of glimepiride tablets and evaluation of in vivo-in vitro correlation[J]. Pharm Today(今日药学), 2020,27(1):1-10.
[4] XIE L, CHEN H, ZHANG Y, et al. Dissolution determination of metronidazole oral sticking tablets by flow-through cell method[J]. China Pharm (中国药师), 2020, 23(4):761-764.
[5] HAN X, PI J X,ZHANG Y, et al. Study on the determination of five indexes dissolution in xiaomi suppository by flow-cell dissolution method[J]. J Tianjin Univ Tradit Chin Med(天津中医药大学学报), 2018, 37(6):511-515.
[6] ZHANG N, FANG X M, HUANG S J, et al. Primary discuss on flow-cell elution release test method at stability of rapamycin on drug-eluting stents[J]. Chin J Pharm Anal(药物分析杂志), 2012, 32(4):575-577.
[7] RAWAT A, BHARDWAJ U, BURGESS D J. Comparison of in vitro-in vivo release of Risperdal® Consta® microspheres[J]. Int J Pharm, 2012, 434(1-2):115-121.
[8] ANDREAS C J, CHEN Y C, MARKOPOULOS C, et al. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release[J]. Eur J Pharm Biopharm, 2015, 97(Pt A):39-50.
[9] ANDREAS C J, PEPIN X, MARKOPOULOS C, et al. Mechanistic investigation of the negative food effect of modified release zolpidem[J]. Eur J Pharm Sci, 2017, 102:284-298.
[10] MARKOPOULOS C, VERTZONI M, SYMILLIDES M, et al. Two-stage single-compartment models to evaluate dissolution in the lower intestine[J]. J Pharm Sci, 2015, 104(9):2986-2997.
[11] YAMAGUCHI I S, KAMBAYASHI A, KOJIMA H, et al. Prediction of the oral pharmacokinetics and food effects of gabapentin enacarbil extended-release tablets using biorelevant dissolution tests[J]. Biol Pharm Bull, 2018, 41(11):1708-1715.
[12] APRSKÁŘOVÁ A, MOŽNÁ P, OGA E F, et al. Instrumentation of flow-through USP IV dissolution apparatus to assess poorly soluble basic drug products: a technical note[J]. AAPS Pharm Sci Tech, 2016, 17(5):1261-1266.
[13] BHATTACHAR S N, WESLEY J A, FIORITTO A, et al. Dissolution testing of a poorly soluble compound using the flow-through cell dissolution apparatus[J]. Int J Pharm, 2002, 236(1-2):135-143.
[14] LETCHMANAN K, SHEN S C, NG W K, et al. Enhanced dissolution and stability of artemisinin by nano-confinement in ordered mesoporous SBA-15 particles[J]. J Microencapsul, 2015, 32(4):390-400.
[15] MEDINA J R, SALAZAR D K, HURTADO M, et al. Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system[J]. Saudi Pharm J, 2014, 22(2):141-147.
[16] BIELEN N. Performance of USP calibrator tablets in flow-through cell apparatus[J]. Int J Pharm, 2002, 233(1-2):123-129.
[17] MILLER J H, DANIELSON T, PITHAWALLA Y B, et al. Method development and validation of dissolution testing for nicotine release from smokeless tobacco products using flow-through cell apparatus and UPLC-PDA[J]. J Chromatogr B Anal Technol Biomed Life Sci, 2020, 1141:122012-122063.
[18] YOSHIDA H, KUWANA A, SHIBATA H, et al. Particle image velocimetry evaluation of fluid flow profiles in USP 4 flow-through dissolution cells[J]. Pharm Res, 2015, 32(9):2950-2959.
[19] FORREST W P, REUTER K G, SHAH V, et al. USP apparatus 4: a valuable in vitro tool to enable formulation development of long-acting parenteral (LAP) nanosuspension formulations of poorly water-soluble compounds[J]. AAPS Pharm Sci Tech, 2018, 19(1):413-424.
[20] VOISINE J M, ZOLNIK B S, BURGESS D J. In situ fiber optic method for long-term in vitro release testing of microspheres[J]. Int J Pharm, 2008, 356(1-2):206-211.
[21] RUDD N D, REIBARKH M, FANG R, et al. Interpreting in vitro release performance from long-acting parenteral nanosuspensions using USP-4 dissolution and spectroscopic techniques[J]. Mol Pharm, 2020, 17(5):1734-1747.
[22] RUDD N D, HELMY R, DORMER P G, et al. Probing in vitro release kinetics of long-acting injectable nanosuspensions via Flow-NMR spectroscopy[J]. Mol Pharm, 2020, 17(2):530-540.
[23] GONZALEZ M A, SMITH D F. Use of IVIVC in the development of oral extended-release formulations: a personal perspective[J]. Dis Technol, 2015, 22(2):35-42.
[24] ANDHARIYA J V, CHOI S, WANG Y, et al. Accelerated in vitro release testing method for naltrexone loaded PLGA microspheres[J]. Int J Pharm, 2017, 520(1-2):79-85.
[25] SHEN J, CHOI S, QU W, et al. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres[J]. J Controlled Release, 2015, 218:2-12.
[26] ANDHARIYA J V, SHEN J, CHOI S, et al. Development of in vitro-in vivo correlation of parenteral naltrexone loaded polymeric microspheres[J]. J Controlled Release, 2017, 255:27-35.
[27] KRÄMER J, STIPPLER E. Experiences with USP apparatus 4 Calibration[J]. Dis Technol, 2005,12(1):33-39.
[28] YOSHIDA H, KUWANA A, SHIBATA H, et al. Effects of pump pulsation on hydrodynamic properties and dissolution profiles in flow-through dissolution systems (USP 4)[J]. Pharm Res, 2016, 33(6):1327-1336.
[29] SPEER I, PREIS M, BREITKREUTZ J. Novel dissolution method for oral film preparations with modified release properties[J]. AAPS Pharm Sci Tech, 2018, 20(1):7.
[30] SIEVENS-FIGUEROA L, PANDYA N, BHAKAY A, et al. Using USP Ⅰ and USP Ⅳ for discriminating dissolution rates of nano- and microparticle-loaded pharmaceutical strip-films[J]. AAPS Pharm Sci Tech, 2012, 13(4):1473-1482.
[31] YAMAMOTO Y, KUMAGAI H, HANEDA M, et al. The mechanism of solifenacin release from a pH-responsive ion-complex oral suspension in the fasted upper gastrointestinal lumen[J]. Eur J Pharm Sci, 2020, 142:105107.
[32] TIPNIS N P, SHEN J, JACKSON D, et al. Flow-through cell-based in vitro release method for triamcinolone acetonide poly (lactic-co-glycolic) acid microspheres[J]. Int J Pharm, 2020, 579:119130.
[33] MCCARTHY C A, FAISAL W, O'SHEA J P, et al. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation[J]. J Controlled Release, 2017, 250:86-95.
[34] DíAZ DE LEÓN-ORTEGA R, D'ARCY D M, BOLHUIS A, et al. Investigation and simulation of dissolution with concurrent degradation under healthy and hypoalbuminaemic simulated parenteral conditions-case example Amphotericin B[J]. Eur J Pharm Biopharm, 2018, 127:423-431.
[35] ANDREAS C J, TOMASZEWSKA I, MUENSTER U, et al. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine[J]. Eur J Pharm Biopharm, 2016, 105:193-202.
[36] EMARA L H, EL-ASHMAWY A A, TAHA N F. Stability and bioavailability of diltiazem/polyethylene oxide matrix tablets[J]. Pharm Dev Technol, 2018, 23(10):1057-1066.
[37] STERNER B, HARMS M, WEIGANDT M, et al. Crystal suspensions of poorly soluble peptides for intra-articular application: a novel approach for biorelevant assessment of their in vitro release[J]. Int J Pharm, 2014, 461(1-2):46-53.
[38] VOSSEN A C V, HANFF L M, VULTO A G, et al. Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam[J]. Br J Clin Pharmacol, 2019, 85:1728-1739.
[39] MILANOWSKI B, HEJDUK A, BAWIEC M A, et al. Biorelevant in vitro release testing and in vivo study of extended-release niacin hydrophilic matrix tablets[J]. AAPS Pharm Sci Tech, 2020, 21(3):83.
[40] LIASKONI A, WILDMAN R D, ROBERTS C J. 3D printed polymeric drug-eluting implants[J]. Int J Pharm, 2021,597:120330-120342.
[41] ZARMPI P, FLANAGAN T, MEEHAN E, et al. Biopharmaceutical implications of excipient variability on drug dissolution from immediate release products.[J] Eur J Pharm Biopharm, 2020, 154:195-209.
[42] FENG X, ZIDAN A, KAMAL N S, et al. Assessing drug release from manipulated abuse deterrent formulations.[J]. AAPS Pharm Sci Tech, 2020, 21(2):40-51.
[43] KUSHWAH V, ARORA S, KATONA M T, et al. On absorption modeling and food effect prediction of rivaroxaban, a BCS II drug orally administered as an immediate-release tablet[J]. Pharmaceutics, 2021, 13(2):283-305.
[44] LI H, ZHAO Y Q, JIANG N Y H, et al. A new method based on flow-through cell apparatus to evaluate dissolution consistency of nimodipine tablets[J]. J China Pharm Univ(中国药科大学学报), 2018, 49(3):301-309.
[45] QIAO Y, CAO Y, YU K, et al. Preparation and antitumor evaluation of quercetin nanosuspensions with synergistic efficacy and regulating immunity[J]. Int J Pharm, 2020, 589:119830.
[46] MARTIN B, GARRAIT G, BEYSSAC E, et al. Organogel nanoparticles as a new way to improve oral bioavailability of poorly soluble compounds[J]. Pharm Res, 2020, 37(6):92.
[47] SHEN J, LEE K, CHOI S, et al. A reproducible accelerated in vitro release testing method for PLGA microspheres[J]. Int J Pharm, 2016, 498(1-2):274-282.
[48] ANDHARIYA J V, BURGESS D J. Recent advances in testing of microsphere drug delivery systems[J]. Expert Opin Drug Deliv, 2016, 13(4):593-608.
[49] KOHNO M, ANDHARIYA J V, WAN B, et al. The effect of PLGA molecular weight differences on risperidone release from microspheres[J]. Int J Pharm, 2020, 582:119339.
[50] SPEER I, PREIS M, BREITKREUTZ J. Dissolution testing of oral film preparations: experimental comparison of compendial and non-compendial methods[J]. Int J Pharm, 2019, 561:124-134.
[51] HORI S, KAWADA T, KOGURE S, et al. Comparative release studies on suppositories using the basket, paddle, dialysis tubing and flow-through cell methods I. Acetaminophen in a lipophilic base suppository[J]. Pharm Dev Technol, 2017, 22(1):130-135.
[52] PRUESSMANN K, WENTZLAFF M, SCHILLING R, et al. Influence of dissolution vessel geometry and dissolution medium on in vitro dissolution behaviour of triamterene-coated model stents in different test setups[J]. AAPS Pharm Sci Tech, 2019, 20(1):27.
[53] SEIDLITZ A, SCHICK W, RESKE T, et al. In vitro study of sirolimus release from a drug-eluting stent: comparison of the release profiles obtained using different test setups[J]. Eur J Pharm Biopharm, 2015, 93:328-338.
[54] MA X, OYAMADA S, GAO F, et al. Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies[J]. J Pharm Biomed Anal, 2011, 54(4):807-811.
[55] KAMBERI M, NAYAK S, MYO-MIN K, et al. A novel accelerated in vitro release method for biodegradable coating of drug eluting stents: insight to the drug release mechanisms[J]. Eur J Pharm Sci, 2009, 37(3-4):217-222.
[56] NEUBERT A, STERNBERG K, NAGEL S, et al. Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents[J]. J Controlled Release, 2008, 130(1):2-8.